CD19 and cancer: Although comparison of CARs against different targets should be interpreted with caution, it is encouraging that the potency of the STEAP1 CAR in in vitro assays matched the activity of the CD19 CAR that has an identical design to tisagenlecleucel (Kymriah), which is in clinical use and highly effective in advanced cancer patients.33